Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Rheumatology Therapeutics Market Forecast: Value Set To Climb From $46.16 Billion To $54.16 Billion
The rheumatology therapeutics market size has experienced consistent growth in recent years. It is anticipated to expand from $44.18 billion in 2025 to $46.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.5%. This historical expansion can be attributed to the rising incidence of rheumatoid arthritis and osteoarthritis, increased access to NSAIDs and corticosteroids, better diagnostic methods for rheumatic diseases, improved healthcare accessibility in mature markets, and an uptick in the use of conventional synthetic DMARDs.
The rheumatology therapeutics market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $54.16 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.1%. Factors contributing to this growth trajectory during the projection period include an escalating demand for biologic DMARDs, a rising elderly demographic suffering from chronic joint conditions, enhanced recognition of the importance of prompt diagnosis and intervention, the proliferation of targeted synthetic DMARDs, and increased spending on chronic illness care. Key developments expected within the forecast timeframe encompass the expanding acceptance of biologic and targeted DMARDs, a move towards proactive and intensive disease management, greater application of combination therapies for rheumatic conditions, an elevated emphasis on sustained disease remission, and the broadening of individualized treatment strategies within rheumatology.
Get A Free Sample Report With In-Depth Market Insights:
Rheumatology Therapeutics Market Expansion Drivers: What’s Shaping Future Growth?
The expanding incidence of autoimmune conditions is anticipated to fuel the expansion of the rheumatology therapeutics market in the future. An autoimmune disease is characterized by the immune system erroneously targeting and harming the body’s own tissues. The increasing occurrence of autoimmune diseases stems from a blend of genetic, environmental, and lifestyle elements, alongside heightened awareness and more sophisticated diagnostic methods. Rheumatology therapeutics are essential for autoimmune diseases to control inflammation, ease symptoms, and avert harm to joints and tissues resulting from the immune system’s assault on the body. For example, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that approximately 514,000 people in Australia, representing 2.0% of the population, were estimated to have been living with rheumatoid arthritis in 2022. In 2023, rheumatoid arthritis was responsible for 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions. Consequently, the escalating prevalence of autoimmune diseases is a key driver for the growth of the rheumatology therapeutics market.
Rheumatology Therapeutics Market Segmentation: How Does The Market Break Down By Category?
The rheumatology therapeutics market covered in this report is segmented –
1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications
Subsegments:
1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs
3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids
4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase
5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics
Rheumatology Therapeutics Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies within the rheumatology therapeutics market are innovating, introducing solutions such as intravenous (IV) formulations to improve treatment effectiveness and patient convenience. An intravenous (IV) formulation describes a medicine or substance administered directly into a vein using a needle or catheter. For instance, in October 2023, Novartis AG, a pharmaceutical firm based in Switzerland, announced the US Food and Drug Administration (FDA) had granted approval for Cosentyx, an intravenous (IV) formulation. This particular version of Cosentyx holds unique approval for treating adults diagnosed with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Its mechanism involves specifically targeting and inhibiting interleukin-17A (IL-17A), making it the sole non-tumor necrosis factor alpha (TNF-a) IV treatment available for these specific ailments.
Rheumatology Therapeutics Market Competitive Overview And Top Companies
Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., UCB S.A., Sanofi SA, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Janssen Biotech, Genentech Inc., Galapagos NV
View The Full Rheumatology Therapeutics Market Report:
Rheumatology Therapeutics Market Geographic Spread And Regional Opportunities
North America was the largest region in the rheumatology therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
